Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

Novo Nordisk, the maker of popular weight loss drugs Wegovy and Ozempic, did not immediately provide detailed reasons for ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

More than one million people in the UK are already paying for the appetite-suppressing drug, from private clinics which ...

Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs. The ...

Shares in Novo Nordisk fell as much as 3.5 per cent on Monday after detailed trial data on its experimental obesity drug ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...

Chief Executive Antonio Filosa shuffled responsibilities within the Jeep parent company and he retained the role of head of North America and American brands. The electric-car maker launches a ...

In addition, the company reported a 21% mean weight loss in a higher dose cohort of the 7.2 mg formulation of Wegovy ...

Over the next 12 years through NHS primary care providers, 1.6 million people are expected to receive tirzepatide, a weight ...

This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost ...